State Of Alaska, Department Of Revenue Amgen Inc Transaction History

State Of Alaska, Department Of Revenue

$8.78 Billion
Q1 2024

A detailed history of State Of Alaska, Department Of Revenue transactions in Amgen Inc stock. As of the latest transaction made, State Of Alaska, Department Of Revenue holds 79,686 shares of AMGN stock, worth $24.7 Million. This represents 0.26% of its overall portfolio holdings.

Number of Shares

79,686

Previous 72,786 9.48%

Holding current value

$24.7 Million

Previous $21 Million 8.08%

% of portfolio

0.26%

Previous 0.25%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 19, 2024	BUY	$268.87 - $324.56 $1.86 Million - $2.24 Million	6,900 Added 9.48%	79,686 $22.7 Million
Q4 2023 Jan 19, 2024	SELL	$255.7 - $288.46 $956,318 - $1.08 Million	-3,740 Reduced 4.89%	72,786 $21 Million
Q3 2023 Oct 16, 2023	SELL	$218.65 - $271.46 $567,396 - $704,438	-2,595 Reduced 3.28%	76,526 $20.6 Million
Q2 2023 Jul 24, 2023	SELL	$214.27 - $253.37 $2.55 Million - $3.01 Million	-11,895 Reduced 13.07%	79,121 $17.6 Million
Q1 2023 Apr 17, 2023	SELL	$225.79 - $275.2 $221,274 - $269,696	-980 Reduced 1.07%	91,016 $22 Million

Q4 2022 Jan 11, 2023	BUY	$229.03 - $291.01 $174,749 - $222,040	763 Added 0.84%	91,996 $24.2 Million
Q3 2022 Oct 20, 2022	SELL	$224.46 - $253.15 $747,676 - $843,242	-3,331 Reduced 3.52%	91,233 $20.6 Million
Q2 2022 Jul 08, 2022	SELL	$230.71 - $256.74 $3.8 Million - $4.23 Million	-16,485 Reduced 14.84%	94,564 $23 Million
Q1 2022 Apr 14, 2022	SELL	$219.27 - $242.57 $1.09 Million - $1.21 Million	-4,985 Reduced 4.3%	111,049 $26.9 Million
Q4 2021 Jan 12, 2022	SELL	$198.88 - $227.6 $2 Million - $2.29 Million	-10,071 Reduced 7.99%	116,034 $26.1 Million
Q3 2021 Oct 07, 2021	SELL	$212.27 - $248.7 $1.47 Million - $1.73 Million	-6,943 Reduced 5.22%	126,105 $26.8 Million
Q2 2021 Jul 12, 2021	SELL	$233.58 - $259.14 $72,643 - $80,592	-311 Reduced 0.23%	133,048 $32.4 Million
Q1 2021 Apr 09, 2021	SELL	$221.91 - $258.6 $1.03 Million - $1.21 Million	-4,661 Reduced 3.38%	133,359 $33.2 Million
Q4 2020 Jan 08, 2021	SELL	$216.38 - $257.67 $3.2 Million - $3.81 Million	-14,787 Reduced 9.68%	138,020 $31.7 Million
Q3 2020 Oct 05, 2020	BUY	$234.65 - $260.95 $4.63 Million - $5.14 Million	19,716 Added 14.81%	152,807 $38.8 Million
Q2 2020 Jul 06, 2020	BUY	$197.81 - $242.74 $5.06 Million - $6.2 Million	25,557 Added 23.77%	133,091 $31.4 Million
Q1 2020 Apr 06, 2020	BUY	$182.24 - $241.7 $863,999 - $1.15 Million	4,741 Added 4.61%	107,534 $21.8 Million
Q4 2019 Jan 07, 2020	SELL	$189.21 - $243.2 $1.71 Million - $2.2 Million	-9,043 Reduced 8.09%	102,793 $24.8 Million
Q3 2019 Oct 02, 2019	BUY	$174.11 - $208.62 $3.41 Million - $4.09 Million	19,592 Added 21.24%	111,836 $21.6 Million
Q2 2019 Jul 23, 2019	BUY	$166.7 - $195.41 $128,692 - $150,856	772 Added 0.84%	92,244 $17 Million
Q1 2019 Apr 09, 2019	SELL	$180.87 - $203.88 $702,860 - $792,277	-3,886 Reduced 4.08%	91,472 $17.4 Million
Q4 2018 Jan 10, 2019	SELL	$178.4 - $208.25 $154,851 - $180,761	-868 Reduced 0.9%	95,358 $18.6 Million
Q3 2018 Oct 09, 2018	SELL	$185.29 - $208.89 $221,606 - $249,832	-1,196 Reduced 1.23%	96,226 $19.9 Million
Q2 2018 Jul 10, 2018	BUY	$166.05 - $186.51 $2.88 Million - $3.24 Million	17,350 Added 21.67%	97,422 $18 Million
Q1 2018 Apr 19, 2018	BUY	$169.43 - $198.0 $1.32 Million - $1.54 Million	7,790 Added 10.78%	80,072 $13.6 Million
Q4 2017 Jan 19, 2018	BUY	$168.79 - $188.59 $11.1 Million - $12.4 Million	65,752 Added 1006.92%	72,282 $12.6 Million
Q3 2017 Oct 16, 2017	BUY	$167.29 - $191.0 $1.09 Million - $1.25 Million	6,530	6,530 $1.22 Million

Others Institutions Holding AMGN

# of Institutions

2,933

Shares Held

401M

Call Options Held

6.59M

Put Options Held

6.6M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $165B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Alaska, Department Of Revenue, based on Form 13F filings with the SEC.

News

Stay updated on State Of Alaska, Department Of Revenue with notifications on news.

Account

State Of Alaska, Department Of Revenue Amgen Inc Transaction History